EcoDrugPlus

Protein Kinase Camp-Activated Catalytic Subunit Beta

Ensembl ID : ENSSARG00000014492
Gene Symbol: PRKACB
1 External references
297 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSSARG00000009925
Gene Symbol: PRKDC
1 External references
184 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSSARG00000003209
Gene Symbol: PTPRB
1 External references
264 Possible Orthologues:

Purine Nucleoside Phosphorylase

Ensembl ID : ENSSARG00000008651
Gene Symbol: PNP
1 External references
429 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSSARG00000001946
Gene Symbol: P2RX7
1 External references
187 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSSARG00000001311
Gene Symbol: RIPK1
3 External references
197 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSSARG00000003129
Gene Symbol: RARB
1 External references
450 Possible Orthologues:

Ribosomal Protein L11

Ensembl ID : ENSSARG00000010904
Gene Symbol: RPL11
1 External references
170 Possible Orthologues:

Ribosomal Protein L15

Ensembl ID : ENSSARG00000004469
Gene Symbol: RPL15
3 External references
110 Possible Orthologues:

Ribosomal Protein L23a

Ensembl ID : ENSSARG00000007120
Gene Symbol: RPL23A
1 External references
133 Possible Orthologues:

Ribosomal Protein L24

Ensembl ID : ENSSARG00000007615
Gene Symbol: RPL24
1 External references
300 Possible Orthologues:

Ribosomal Protein L26

Ensembl ID : ENSSARG00000005798
Gene Symbol: RPL26
3 External references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).